SPECIAL REPORT

Numerous head-to-head trials in multiple sclerosis have demonstrated the benefits of treatment with a higher-efficacy versus modest-efficacy disease-modifying therapy (DMT). Examples include the TRANSFORMS (fingolimod vs. interferon-b), CARE-MS (alemtuzumab vs. interferon-b), OPERA I/II (ocrelizumab vs. interferon-b), and ASCLEPIOS I/II (ofatumumab vs. teriflunomide) trials in relapsing MS. Read More

Two pioneers in MS nursing have joined the list of Canadian recipients of the Giants of MS award, presented by the Consortium of MS Centers (CMSC). Read More

Geography has a significant impact on MS patients’ access to care and treatment options, according to data presented at the Consortium of MS Centers (CMSC) 38^th annual meeting, held May 29-June 1 in Nashville, Tennessee. Read More